Changes in Beneficial Ownership · 4
AEON Biopharma, Inc.
AEONNYSE_AMERICANEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-19
- Issuer
- AEON Biopharma, Inc.
- Issuer CIK
- 0001837607
- Trading symbol
- AEON
Reporting owner 1
- Name
- LYNCH TIMOTHY P
- Reporting owner CIK
- 0001270925
- Relationship
- 10% owner
- Address
- 70 SW CENTURY DR., STE. 100, BEND, OR, 97702
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-08-19 | P · Form 4 | 1,150,000 | A | 0.2117[F1] | 6,500,000 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Timothy P. Lynch
- Date
- 2026-08-21
Company context
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.